semaglutide oral ACC 2025: Reduces Cardiovascular Events by 14% at 4 Years US FDA accepts Novo Nordisk's

Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on managements current expectations and assumptions and are subject to risks and uncertainties

In support of this, ICV administration of GLP-1 in rats has been shown to attenuate the fasting-induced rise in NPY/AgRP expression and decreases fasting-induced inhibition of POMC/CART expression in the ARC (Seo et al., 2008)

GLP-1 1(2.5mg) 7,000 7,700 1(5.0mg) 12,000 13,200 GLP-1 GLP-1 GLP-1 GLP-1 GLP- GLP-1 01. GLP-1 02. 03. GLP-1 GLP-1 BMI 3 2GIPGLP-1-1GIPGLP-1 2GIPGLP-1GLP-1 1 12.5mg2.5mg45mg15 mg4 GLP-197FDAGLP-11 11 0.611.2mg11.8mg 1.8mg GLP-1 GLP-1 111 1() 3~4 0.25mg40.5mg 40.5mg1.0mg 34 GLP-1 11 GLP-1 GLP-1 GLP-1 Q 1 A 1 Q A GLP-112122 Q A Q A 40 Q A GLP-12 92(BMI)27 Q A GLP-112122 Q A GLP-111 Q 1 A GLP-11180.630 Q A GLP-1 Q A FDA GLP-1

A study indicated that tirzepatide ameliorates high glucose-induced damage to nerve cells (Lin et al., 2023)

AND ALREADY OSTEOPOROSIS IS UNDERDIAGNOSED AND UNDERTREATED